EN DE
Watch NeoCore Technology Co., Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NeoCore Technology Co., Ltd. (4131) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of NeoCore Technology Co., Ltd. stock TWD 24.09, price TWD 30.55, that is 21.1% below the price, quality 40 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

NT NeoCore Technology Co., Ltd. logo Thin data Nov 10, 2026

NeoCore Technology Co., Ltd.

4131 · TWO

Expensive (fair value 21% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Ranks above peers (7/9) 
Revenue last quarter +78% vs. a year ago. 
Quality 40/100 
Fair value 24.09 TWD · Overvalued 
Weak Growth (revenue 3y −11.5 %/yr in TWD) 
Loss-making · -11.9% net margin (TTM) 
Negative free cash flow 
Narrow moat 11/100 · thin data
Thin data 
Estimate
Watch NeoCore Technology Co., Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

43.60 TWD 13.10 TWD Fair Value 24.09 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 13.10 TWD – 43.60 TWD · fair‑value band 18.07 TWD – 30.11 TWD · the 30.55 TWD price screens above the 24.09 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow NeoCore Technology Co. in your weekly email

Every Wednesday you see whether NeoCore Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NeoCore Technology Co., Ltd. designs, manufactures, and sells biochips and rapid nucleic acid hybridization devices.

Show moreShow less

The company's products include food safety examination systems, human diagnosis arrays systems, agriculture examination systems, food examination arrays systems, and laboratory instruments, as well as DNA kits. It also offers laboratory planning, design, and other services.

In addition, the company engages in the wholesale and retail of contact lenses. The company was formerly known as DR. Chip Biotechnology Incorporation and changed its name to NeoCore Technology Co., Ltd. in July 2023.

NeoCore Technology Co., Ltd. was founded in 1987 and is headquartered in Tainan City, Taiwan.

Stock analysis

NeoCore Technology Co., Ltd. (4131) currently trades at 30.55 TWD, while our estimate is 24.09 TWD, 21% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 18.07 TWD (bear) to 30.11 TWD (bull), the price of 30.55 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

NeoCore Technology Co., Ltd. reported revenue of 61.5M TWD in FY2024 versus 88.9M TWD in FY2021, a compound −11.5%/yr. Reported net income was −48.1M TWD in FY2024.

Key figures

Market cap 1.2B TWD (≈ $36.7M) Micro · P/S ratio 4.52 · EPS (TTM) −0.8300 TWD · Net margin −11.9% · Return on equity −10.6% · Return on assets (EBIT) −15.7% (4-year average) · Operating margin 4.7% · Revenue growth (YoY) +78.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 11 out of 100 (low confidence).

What moves the price

The share trades about 27% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −21%, 4131 screens richer than that median.

Fair Value

Bear 18.07 TWD Fair Value 24.09 TWD Bull 30.11 TWD
Price 30.55 TWD · Downside -21.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 62
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 23
Does it invest with discipline instead of growing at any price?
Low Volatility 85
How calm the share price moves, does not count
Price momentum 33
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 19
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−4.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−31.8% (2021) → −123.2% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2024 is a loss year, no rate is defined from a loss
not computed

4131 screens overvalued: fair value 21% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare NeoCore Technology Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 853 stocks

Beats the industry median on 6/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 40 · Above median
Fair Value upside −21.1% · Above median
Profitability
Return on assets −14.1% · Above median
Net margin (12 months) −11.9% · Below median
Operating margin (12 months) 4.7% · Above median
Growth and dividend
Revenue growth (quarter YoY) 78.2% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.96× · Pricier than median
P/S (12 months) 4.35× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)5 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $955.47 $1,275 +33% vs 4131
Genmab A/S GMAB kr 3,448 kr 3,917 +14% vs 4131
Vertex Pharmaceuticals Incorporated VRTX $538.60 $592.46 +10% vs 4131
Samsung Biologics Co 207940 1,411,000 KRW 1,552,100 KRW +10% vs 4131
argenx SE ARGX $960.04 $908.40 −5% vs 4131
CSL Limited CSL A$202.92 A$183.54 −10% vs 4131
Moderna, Inc MRNA $223.37 $139.99 −37% vs 4131
BeOne Medicines AG 6160 HK$249.80 HK$152.80 −39% vs 4131
Celltrion, Inc 068270 214,000 KRW 74,945 KRW −65% vs 4131
Royalty Pharma plc RPRX $69.31 $19.01 −73% vs 4131

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NeoCore Technology Co., Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NeoCore Technology Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/4131

Frequently asked questions

Is NeoCore Technology Co., Ltd. (4131) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 24.09 TWD versus a price of 30.55 TWD, about 21% lower (overvalued).
What is the fair value of 4131?
Our estimate for NeoCore Technology Co., Ltd. is 24.09 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 30.55 TWD.
What is the quality score of 4131?
NeoCore Technology Co., Ltd. has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NeoCore Technology Co., Ltd. (4131)?
Our calculated price target is the estimate of 24.09 TWD (as of Nov 10, 2026). Cautious scenario 18.07 TWD, optimistic scenario 30.11 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NeoCore Technology Co., Ltd. stock forecast for 2026?
Our estimate puts fair value at 24.09 TWD, about 21% lower versus a price of 30.55 TWD (overvalued). Cautious scenario 18.07 TWD, optimistic scenario 30.11 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NeoCore Technology Co., Ltd. (4131)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NeoCore Technology Co., Ltd. it is 24.09 TWD per share (as of Nov 10, 2026), against a price of 30.55 TWD.
Is NeoCore Technology Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 4131 trades above its calculated fair value: price 30.55 TWD, fair value 24.09 TWD, a gap of about −21% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4131?
No. The price is what the market pays today (30.55 TWD); the fair value is what the company's own numbers justify (24.09 TWD). For NeoCore Technology Co., Ltd. the two are 6.46 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is NeoCore Technology Co., Ltd. worth?
The market values NeoCore Technology Co., Ltd. at about 1.2B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 30.55 TWD; our models calculate a fair value of 24.09 TWD per share.
What do the bullish and bearish scenarios say about 4131?
Our models span a range for NeoCore Technology Co., Ltd.: cautious scenario 18.07 TWD, base 24.09 TWD, optimistic 30.11 TWD per share (as of Nov 10, 2026, price 30.55 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of NeoCore Technology Co., Ltd. (4131)?
Balance-sheet figures for NeoCore Technology Co., Ltd. (as of Nov 10, 2026): return on equity −10.6%. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 4131 from its 52-week high?
NeoCore Technology Co., Ltd. trades at 30.55 TWD, about 27% below its 52-week high of 42.00 TWD and 2% above the low of 29.90 TWD (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of 24.09 TWD is for.
Which stocks are comparable to NeoCore Technology Co., Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NeoCore Technology Co., Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 30.55 TWD, calculated fair value 24.09 TWD (−21%), Quality Score 40/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. NeoCore Technology Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NeoCore Technology Co., Ltd. (4131)?
The closing price on Nov 13, 2026 was 30.55 TWD. Our estimate is 24.09 TWD, about 21% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NeoCore Technology Co., Ltd. right now?
Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of NeoCore Technology Co., Ltd.

How large is the market capitalisation of NeoCore Technology Co., Ltd. (4131)?
The market capitalisation of NeoCore Technology Co., Ltd. is 1.2B TWD (≈ $36.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of NeoCore Technology Co., Ltd. (4131)?
The price-to-sales ratio of NeoCore Technology Co., Ltd. is 4.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of NeoCore Technology Co., Ltd. (4131)?
Earnings per share at NeoCore Technology Co., Ltd. are −0.8300 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of NeoCore Technology Co., Ltd. (4131)?
The net margin of NeoCore Technology Co., Ltd. is −11.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of NeoCore Technology Co., Ltd. (4131)?
The return on equity (ROE) of NeoCore Technology Co., Ltd. is −10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of NeoCore Technology Co., Ltd. (4131)?
On an EBIT basis the return on assets of NeoCore Technology Co., Ltd. is −15.7% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of NeoCore Technology Co., Ltd. (4131)?
The operating margin of NeoCore Technology Co., Ltd. is 4.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at NeoCore Technology Co., Ltd. (4131)?
Revenue at NeoCore Technology Co., Ltd. is growing 78.2% versus a year earlier (3y avg −11.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does NeoCore Technology Co., Ltd. (4131) generate?
The free cash flow of NeoCore Technology Co., Ltd. is −69.7M TWD (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch NeoCore Technology Co., Ltd. in the live analysis

One click puts NeoCore Technology Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.